OCS-05 neuroprotective therapy for MS shows good safety profile
OCS-05, a neuroprotective treatment candidate being developed by Oculis for multiple sclerosis (MS) or other causes of optic nerve inflammation, demonstrated a favorable safety and pharmacological profile in healthy volunteers, according to Phase 1 trial data. AÂ Phase 2 trial (NCT04762017), called ACUITY, is now evaluating OCS-05’s…